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Monocytes are known to secrete upon LPS stimulation large amounts of a
neutrophil-activating peptide originally termed MONAP (1), MDNCF (2), NAF
(3), or GCP (4), and now called NAP-1/IL-8 (5) . With respect to the primary se-
quence, this novel cytokine (consisting of 72 amino acids in its major form) shows
structural homology to 0-thromboglobulin-like host defense cytokines (2-4, 6) and
is quite different from other cytokines, such as IL-1 or TNF.
In attempts to purify NAP-1/IL-8 from supernatants of LPS-stimulated mono-
cytesby the use ofHPLC techniques, we reproducibly observed the presence of ad-
ditional neutrophil-stimulating activity eluting at a different retention time than NAP-
1/IL-8 . This indicates that monocytes secrete more than one neutrophil-activating
peptide .
In this study, purification and characterization of a second monocyte-derived
neutrophil-activating cytokine, whichwe tentatively termed NAP-3, will be described .
Our data provide evidence that monocytes upon LPS stimulation are able to secrete
a neutrophil-activating protein identical in its NH2-terminal amino acid sequence
with melanoma growth-stimulating activity (MGSA/gro) t , which is known to be-
long to the same supergene family of(3-thromboglobulin-like host defense cytokines
as NAP-1/IL-8 does .
Materials and Methods
Neutrophil Isolation .
￿
Human polymorphonuclearleukocytes (PMNL) from normalhuman
volunteers were isolated usingamodification of the method of Henson (7), as described (1) .
PMNL preparations were identified to contain 96-98% neutrophils, usually <0.5% eosino-
This work was supported by Deutsche Forschungsgemeinschaft grant Schr 305, 1-2 .
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1 Abbreviations used in thispaper: CI, chemotactic index ; MGSA, melanoma growth-stimulating activ-
ity; PMNL, polymorphonuclear leukocytes.
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phils, and 0.5-2% mononuclear cells. Viability of the final PMNL preparation usually was
>97% (trypan blue exclusion test).
Production ofMonocyte-derived Neutrophil-activating Peptides.
￿
Human monocytes, isolated by
counterflow elutriation (J2-21 M/E centrifuge; Beckman Instruments, Inc., Palo Alto, CA)
of PBMC were incubated with LPS (Salmonella minnesota ; Calbiochem-Behring Corp., Mar-
burg, FRG) (1 Fig/ml) in RPMI 1640 containing 1 mM glutamine and 20 mM Hepes (cell
density, 5 x 106 cells/ml). After a 40-48-h incubation at 37'C, conditioned media were col-
lected and frozen below -70'C until further use.
Purification ofNeutmphil-activating Proteins.
￿
Supernatants ofLPS-stimulating monocytes were
acidified to pH 3, concentrated over Amicon YM-5 filters, and chromatographed on a G-75
gel column (2.5 x 70 cm; Pharmacia Fine Chemicals, Uppsala, Sweden) using 0.1 M ammo-
nium formate, pH 5, as eluent. Fractions containing PMNL chemotaxis-stimulating activ-
ity (eluting in fractions corresponding to the area 40-5 kD) were concentrated and applied
to a preparative wide-pore reversed-phase (RP)-8-HPLC column (300 x 7 Am C8 Nucleosil,
250 x 12 .6 mm; Macherey and Nagel, Duren, FRG) and separated by the use of increasing
concentrations of acetonitrile, as described (8). Fractions were tested either for PMNL che-
motactic activity, PMNL myeloperoxidase release, or both, and fractions containing PMNL-
stimulating activity were further purified by wide-pore CN-propyl-HPLC (5 Am, 250 mm x
4.6 mm; J . T Baker, Gross Gerau, FRG). Peptides were eluted with a gradient of increasing
concentrations of n-propanol containing 0.1% (vol/vol) trifluoroacetic acid. Fractions con-
taining PMNL-stimulating activity were finally purified by narrow-pore RP-18-HPLC
(Nucleosil, 5-Am octadecyl silica column; Bischof,, Leonberg, FRG) using a gradient of ace-
tonitrile in aqueous TEA (0.1% [vol/vol]).
SDS-PAGE.
￿
SDS-PAGE for peptides was performed as described by Schagger and von
Jagow (9) using tricine and a discontinuous system optimized for detection of 1-20-kD poly-
peptides. For separation ofpolypeptides, a gel containing 16.5% T and 6% C in the presence
of 8 M urea was used. Polypeptides were visualized by silver staining (Sigma Chemical Co.,
St. Louis, MO).
NH2-terminalAmino AcidSequence Analysis ofNeutrophil-activating Peptide.
￿
Material made ho-
mogeneous by SDS-PAGE and RP-HPLC was subjected to gas phase sequencing using a
sequencer (470A; Applied Biosystems, Inc., Foster City, CA) with on line HPLC analysis
of the phenylthiohydantoin derivatives.
PMNL Functional Assays.
￿
Chemotactic activity for PMNL was assessed, as recently de-
scribed in detail (1), using a modification of the endogenous component chemotaxis assay
described by Creamer et al. (10). In some experiments, PMNL chemotaxiswas determined
by the use of a microscopic cell counting method, as described (11). Chemotactic activity
was expressed as chemotactic index (CI): CI = No. ofcell equivalents migrating upon stimu-
lation/No. of cell equivalents migrating without stimulation. Release oflysosomal enzymes
in cytochalasin B-pretreated PMNL was determined by estimating the amount of either a-
glucuronidase or myeloperoxidase, as recently described (1).
Deactivation ofchemotaxin-induced lysosomal enzyme release ((3-glucuronidase) was per-
formed, as recently described (1), by preincubating PMNL with chemotaxins followed by
adding cytochalasin B and a second challenge with chemotaxins. Results are expressed as
the percentage of inhibition of net enzyme release by buffer-preincubated cells.
Results and Discussion
Our results show that human monocytes upon stimulation with bacterial LPS se-
crete more than one neutrophil-activating peptide. Although there is no doubt that
NAP-1/IL-8 is by far the most abundant PMNL-activating peptide, supernatants
of LPS-activated monocytes reproducibly show several fractions containing less PMNL
enzyme release, as well as chemotactic response-eliciting activity, which eluted at
lower acetonitrile concentration than NAP-1/IL-8 did (Fig. 1).
One of the major neutrophil-activating proteins eluting at 30-35% acetonitrile
from the RP-8-HPLC column could be purified by different RP-HPLC-techniquesSCHRODER ET AL .
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(Figs . 2 and 3) . This material appears to be homogeneous, giving a single band at
M r 5.3 kD (Fig . 4), which is of similar mobility as that seen for the 8.5-kD protein
NAP-1/IL-8, migratingunder these conditions with an unusual mobility like a 5.8-
kD polypeptide (Fig . 4) .
NH2-terminal amino acid sequence analysis of purified material (Fig. 5) revealed
FIGURE 1 . Preparative wide-
pore RP-HPLC ofneutrophil-
activating peptides . Superna-
tants of LPS-stimulated human
monocytes were partially pu-
rified by G-75 gel filtration . Bi-
ologically active fractions (5-40-
kD area) were separated on a
preparative wide-pore RP-8-
HPLC-columnby the use ofan
increasingconcentration ofac-
etonitrile . Elution of peptides
was monitored at 215 nm . 10-
,al aliquots ofeach fraction were
tested either for secretion of
myeloperoxidase(MPO) in cy-
tochalasin B-pretreatedPMNL
(shaded area) or for chemotactic
activity, as described in Mate-
rials and Methods. Note the ap-
pearance of additional PMNL
enzyme-releasing activity elut-
ing before NAP-1/1L-8 (the elu-
tion position ofauthenticNAP-
1/IL-8 is indicated by the arrow).
FIGURE 2 . CN-propyl-RP-HPLC of the second
monocyte-derived neutrophil-activating protein (NAP-
3). PMNL-activating fractions off preparative RP-
8-HPLC eluting at 30-35% acetonitrile(Fig. 1)were
further purified by CN-propyl-RP-HPLC using a
gradient of increasing concentrations ofn-propanol.
Amajor peak ofPMNL-stimulating activity eluted
at 21 min (NAP-3), whereas a second (minor) one
eluted at higher n-propanol concentration (shaded
area).1094
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FIGURE 3 .
￿
Final RP-18-HPLC purification of the
second monocyte-derived neutrophil-activating pro-
tein . Fractions containing the major PMNL-stim-
ulating activity offCN-propyl-HPLC eluting at35%
n-propanol (Fig . 2) were finally purified by narrow-
pore RP-18-HPLC. Shaded area shows peaks con-
tainingPMNL enzyme release eliciting activity . Note
the presence ofamajorandaminorpeak absorbing
at 215 nm .
it to be identical with that ofthe 13-kD moiety ofMGSA (12), known to be identical
with the product of serum-induced growth-regulated gene, termed gro, which is
differentially expressed by some human cell lines (13) .
Whetherthe second monocyte-derived neutrophil-activating peptide we tentatively
termed NAP-3 (because in a recent investigation, another structurally related neu-
trophil-activating peptide identical to apossibly platelet-derived fragment of/3-throm-
boglobulin was detected in mononuclear cell supernatants, which was tentatively
termed NAP-2 [14]) is, with respect to its COOH-terminal amino acid sequence
and molecular weight, identical with MGSA is yet not clear. TheM r originally re-
ported for a MGSA preparation showing identical NH2-terminal amino acid se-
quence, as we found for NAP-3, has been estimated to be 13 kD (12) . For NAP-3,
we found aM r of-5.3 kD when a tricine-SDS-PAGE system together with CN-Br
cleavage products of myoglobin as standards were used (Fig . 4) . However, in a very
recent report about the secretion of MGSA/gro by stimulated endothelial cells, a
FIGURE 4.
￿
SDS-PAGE ofthe second monocyte-
derived neutrophil-activating protein . Material
obtained from the RP-18-HPLC-purification
(Fig . 3) was analyzed in lanes 5 and 6 for itsM r
by tricine-SDS-PAGE in the presence of8Murea
usingthemethod of Schigger andvonJagow (9) .
Lane 1 contains a mixture ofCNBr cleavage prod-
ucts of myoglobin . In lanes 3 and 4, authentic
NAP-1/IL-8 is applied, whereas lane 2 contains
the 77-residue form ofNAP-1/IL-8 obtained from
IL-1-stimulated fibroblasts (19) . SDS-PAGE was
performedunder nonreducing conditions, except
for the calibration mixture . Note the abnormal
mobility of NAP-1/IL-8, which is known to be a
8.39-kD polypeptide migrating under these con-
ditions as a 5.8-kD polypeptide .SCHRODER ET AL.
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FIGURE 5.
￿
NH2-terminal amino acid
sequence characterization of the sec-
ond monocyte-derived neutrophil-
activating peptide (NAP-3). NH2
NAP-3
￿
ASVATELRXQXLQTLQG IHPKNIQSVNVK?P
￿
terminal amino acid sequencing of
SV
￿
NAP-3 was performed without deriv
L
￿
atization. Therefore, cysteins were de-
tected as blanks (X). The single letter
MGSA
￿
ASVATELRCQCLQTLQG IHPKNIQSVNVKSP. . .
￿
code for amino acids is used. Asterisks
gro
￿
ASVATELRCQCLQTIQG IHPKNIQSVNVKSP. . .
￿
indicate homology with NAP-1/11-8.
(MGSA) Sequence aspublished for the
NAP-1/IL-8
￿
SAKELRCQCIKTYSKPFHPKFIKELRVIES . . .
￿
13-kD moiety ofMGSA (12). (gro) Part
ofthe sequence published for gro (13).
NAP-2
￿
AELRCMCIKTTSG-IHPKNIQSLEVIGK . . .
￿
(NAP-1/1L-8) NH2-terminal sequence
ofNAP-1/11-8 as recently shown (2-4,
6). (NAP-2) N142-terminal sequence
of NAP-2 (14).
M, of-8 kD has been estimated for authentic MGSA made by Hs294 melanoma
cells (15). The difference from the originally described Mr has been attributed to
the use of a different gel system and molecular weight standards. When we used
authentic NAP-1/IL-8, known to be a 8.386-kD polypeptide (6), as Mr standard,
a Mr ofN8 kD could be estimated forNAP-3. This was supported by size exclusion
HPLC of NAP-3, where we estimated a M, of -10 kD (data not shown).
The apparent molecular weight of NAP-3 is consistent with the value predicted
from the amino acid sequence of gro/MGSA (12). Therefore, it appears likely that
NAP-3 and MGSA/gro are identical cytokines. Further support for this suggestion
was obtained from preliminary investigations, when we tested growth stimulatory
activity of a NAP-3 preparation in fibroblasts. In a dose range between 0.5 and 10
ng/ml, NAP-3 showed growth stimulatory activity (unpublished results). This fits
well with the mitogenic behavior reported for MGSA in fibroblasts (15).
Interestingly, sequence analysis ofthe monocyte-derived NAP-3 indicated thepres-
ence ofan NH2-terminal altered form of NAP-3 containing Ser (N50%) instead of
Ala for the NH2-terminal amino acid, as well as either Leu or Val instead of Ser
(ti30%) for the second amino acid. In the following cycles up to residue 31, no evi-
dence for major changes was obtained. These results point towards the possible ex-
istence ofdifferent genetic forms ofNAP-3, although further studies are needed to
support this suggestion.
When NAP-3 was investigated for its PMNL stimulatory properties, it could be
demonstrated that both chemotactic migration, as well as degranulation oflysoso-
mal enzymes, are elicitable (Fig. 6). Interestingly, NAP-3 shows a similar ED5o in
elicitingPMNLchemotaxis when compared with NAP-1/IL-8 (Fig. 6); however, the
number ofmigrating cells at optimal stimulation conditions has been found to be
only 60°Io ofthat seen for potent PMNL chemotaxins like C5a, LTB4, or NAP-1/IL-
8, which was supported by the use of experiments performed with a direct micro-
scopical cell-countingchemotaxismethod (datanotshown). Moreover, thebell-shaped
dose-responsecurve covers a more narrow area than NAP-1/IL-8, giving at concen-
trations >200 ng/ml no significant chemotactic responses (Fig. 6). A similar, more
restricted dose-response profile in PMNL chemotaxis has been reported forplatelet-
derived growth factor (16).1096
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Concentration of Peptide [npiml]
FIGURE 6.
￿
PMNL chemotactic and degranulation-eliciting activity of the second monocyte-
derived neutrophil-activating protein. PMNL chemotactic activities of purified preparations of
NAP-3(O)as well as NAP-1/IL-8 (A) and PMNL degranulation (/3-glucuronidase)-eliciting ac-
tivities of NAP-3 ("), as well as NAP-1/IL-8 (A)as afunction ofthepeptide concentration used
areshown. Shaded bars represent chemotactic indicesofauthenticC5aandLTB4. Degranulation-
eliciting activity with the use of 10-s M FMLP or 10-8 M C5a has been found to be 48 and
35% ofthetotal control, respectively. Data representmean of three duplicateperformed exper-
iments.
Crossdesensitization experiments with NAP-3 and NAP-1/IL-8 show crossreac-
tivities in chemotaxin receptor-dependent PMNL enzyme release by NAP-3 and
NAP-1/IL-8, but not, however, with C5a or FMLP (Table I). This result may sup-
port the suggestion than NAP-3 binds to the PMNL-NAP-1/IL-8 receptor, which
recently has been characterized (17). It appears, however, that NAP-3 is a weaker
agonist than NAP-1/IL-8, because preincubation of PMNL with NAP-1/IL-8 com-
pletely abolished responses to a second challenge with NAP-3, whereas preincuba-
tion ofcells with NAP-3 does not show the same amount ofdeactivation when NAP-
1/IL-8 is used at a similar molar concentration for the second stimulation (Table I).
A PMNL-activating peptide with the same NH2-terminal amino acid sequence
as found for the 16-kD moiety of MGSA/gro (12) was recently isolated from lesional
psoriasic scale material as one of its major peptide-like PMNL chemoattractants
(18). Moreover, we detected in IL-1- or TNFu-stimulated human dermal fibroblasts
a neutrophil-activating peptide termed y-FINAP (19), which is biochemically as well
as biologically identical with the psoriasis-derived MGSA/gro. Both investigations
support the observation of this study that a protein with similarity to MGSA/gro
indeed is a neutrophil-activating factor. The biological significance of the PMNL
function-activating property of NAP-3 remains to be speculative at the moment.
Recent studies have shown that MGSA, which originally has been isolated from
melanomas as well as cultivated melanoma cells (20), apparently acts as a growth
hormone for different cells (12).
Apart from this, autocrine growth-stimulating activity of MGSA/gro is well doc-H
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umented (12, 13, 15, 20). Therefore, it is possible that secretion ofa MGSA/gro-re-
lated protein by LPS-stimulated monocytes could be considered as a mitogenic sig-
nal rather than a signal for PMNL activation upon inflammatory reactions. This
is supported by sequence relatedness ofthis cytokine to both mitogens and neutro-
phil-activating proteins, because MGSA/gro is a memberofthe new supergene fam-
ily ofR-thromboglobulin-like host defense cytokines, as is NAP-1/IL-8 (2-5, 12). It
is noteworthy that mouse macrophages secrete upon endotoxin stimulation a neu-
trophil attractant termed macrophage inflammatory protein 2, which shows strong
sequence homology to human NAP-3 and MGSA/gro (21). However, it appears un-
likely that macrophage inflammatory protein 2 despite its biological properties that
are similarto NAP-3, is themurine equivalent ofMGSA/gro, because anothermem-
ber ofthe(3-thromboglobulin superfamily obtained from PDGFstimulated murine
macrophages, termed KC (22), shows higher sequence homology to human
gro/MGSA.
Some of the members ofthe (3-thromboglobulin superfamilyAike connective tis-
sue-activating peptide III are reported to be mitogenic (23), and NAP-1/IL-8 isknown
to be a powerful PMNL-activating cytokine (1-4).
It appears that MGSA/gro (or a COOH-terminal truncation product) represents
the first member ofthis novel family ofhost defense cytokines, whichexpressesboth
growth-promoting and proinflammatory behavior at the nanogram level.
Summary
Purification ofmonocyte-derived NAP-1/IL-8 bypreparative reversed-phase (RP)-
HPLC led to the detection of a second peak with polymorphonuclear leukocyte
(PMNL)-activating(degranulation, chemotaxis)properties. Themonokine respon-
sible forthis biological activity, which we tentatively termed NAP-3, could be purified
to homogeneity bythreedifferent RP-HPLC steps. Tricine-SDS-PAGE analysisgave
a single line at Mr 5.3 kD (NAP-1/IL-8 = 5.8 kD). NH2-terminal amino acid se-
quence analysis read as a major sequence (ASVATELRXCXLQT. .), which shows
>40% homology to that of NAP-1/IL-8. The sequence is identical to that found for
the 13-kD moiety ofmelanoma growth stimulating activity (MGSA) and the prod-
uct of the oncogene gro.
Determination ofneutrophil chemotactic activity ofNAP-3 revealed atypicalbell-
shaped dose-response curve (ED5o = 2 ng/ml) with no significant neutrophil che-
motactic activity at doses >200 ng/ml. Also,, in cytochalasin B-pretreated PMNL,
NAP-3 elicited release of myeloperoxidase and (3-glucuronidase. Crossdesensitiza-
tion studies in PMNL enzyme release revealed crossreactivities with the NAP-1/IL-
8-R on PMNL. NAP-3 (MGSA/gro) appears to represent the first member of the
novel supergene family of/3-thromboglobulin-like hostdefense cytokines, which ex-
presses both mitogenic aswell asproinflammatoryproperties atthe nanogram level.
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